
    
      This is a phase II, open-label, single-arm, multicenter study conducted in adult subjects
      with relapsed and refractory (R/R) mantle cell lymphoma (MCL) in China to evaluate the
      safety, efficacy, pharmacokinetics(PK), pharmacodynamics(PD) of JWCAR029 and immune response
      after JWCAR029 treatment.

      R/R MCL patients will be enrolled in dose level of 1.0 x 10^8 CAR+ T cells. All subjects will
      be followed for 2 years following JWCAR029 infusion.
    
  